VahatiCor, a medical technology company focused on treating Coronary Microvascular Dysfunction, announced the closing of its $23 million Series B funding round led by S3 Ventures with participation from Intuitive Ventures and a strategic investor. The funds will support ongoing SERRA-I study enrollment, engineering improvements, and preparation for pivotal trials and regulatory submissions.
Health Technology Insights: Broken String Biosciences Names New Leaders to Drive INDUCE-seq
“Securing this funding from such a respected group of investors affirms the value of our therapy and the strength of our team,” said Marwan Berrada-Sounni, Co-Founder of VahatiCor. “This investment enables us to continue advancing A-FLUX through clinical studies, bringing a promising interventional therapy to the millions affected by CMD, with the goal of meaningful symptom relief and improved quality of life worldwide.”
Health Technology Insights: Henry Ford Health Partners with Nomi Health
Coronary Microvascular Dysfunction is a prevalent but often underdiagnosed condition that leads to ongoing angina, chest pressure, and pain despite no major artery blockages. In the United States, three to four million people, predominantly women, show signs of ischemia without obstructive coronary artery disease. Studies indicate these patients face higher annual risks of adverse cardiovascular events and continue to experience symptoms despite standard anti-anginal medications. Current treatment options fail to improve coronary flow directly, leading to frequent hospital visits and repeated testing that rival those of patients with obstructive coronary artery disease.
The A-FLUX Reducer System is designed to enhance myocardial perfusion by creating a controlled narrowing in the coronary sinus, optimizing blood flow to the heart muscle to alleviate angina symptoms. Brian R. Smith, Managing Director at S3 Ventures, commented, “A-FLUX represents a major advancement for a patient population that has been underserved. Its self-expanding and repositionable design offers key advantages in safety and efficacy, positioning VahatiCor as a leader in coronary sinus therapy.”
Terri Burke, Senior Partner at Intuitive Ventures, added, “Patients with CMD suffer from repeated symptoms and reduced quality of life. VahatiCor’s A-FLUX system addresses a critical unmet need, offering a therapy that prioritizes patient outcomes. We are confident in the team’s ability to navigate the clinical path and bring this therapy to market.” VahatiCor also reported significant progress in the SERRA-I early feasibility study, which plans to enroll 30 patients across six sites to evaluate the safety and effectiveness of the A-FLUX system.
Health Technology Insights: Johnson & Johnson to Acquire Halda Therapeutics for Cancer Treatment
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
